Jacobs Levy Equity Management
RPTP

Jacobs Levy Equity Management’s RAPTOR PHARMACEUTICAL CORP COM STK (DE) RPTP Stock Holding History

Jacobs Levy Equity Management’s Portfolio RPTP Stock Details RPTP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-167,700
Closed -$901K – 1260
2016
Q2 		$901K Hold
167,700
– – 0.02% 616
2016
Q1 		$771K Buy
+167,700
New +$674K 0.02% 625

Other funds holding RPTP

AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GLAM
Gardner Lewis Asset Management Chadds Ford, Pennsylvania $462M AUM 65.29% 1-Year Est. Return
OAC
OMERS Administration Corp Toronto, Ontario, Canada $15.6B AUM 24.73% 1-Year Est. Return

Jacobs Levy Equity Management's RPTP Position: Q3 2016 in Review

Jacobs Levy Equity Management sold out of RAPTOR PHARMACEUTICAL CORP COM STK (DE) (RPTP) in Q3 2016, closing a stake of 167,700 shares — an estimated $901K sold.

Jacobs Levy Equity Management first reported a position in RPTP in Q1 2016 and held it in 2 quarters. The position peaked at $901K in Q2 2016. 111 funds tracked by Wall St. Rank hold RPTP as of Q3 2016.

  • Jacobs Levy Equity Management reported no remaining RAPTOR PHARMACEUTICAL CORP COM STK (DE) position as of Q3 2016 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 167,700 RAPTOR PHARMACEUTICAL CORP COM STK (DE) shares in Q3 2016, an estimated $901K.
  • Jacobs Levy Equity Management first reported a position in RAPTOR PHARMACEUTICAL CORP COM STK (DE) in Q1 2016 and held it in 2 quarters.
  • Jacobs Levy Equity Management's RAPTOR PHARMACEUTICAL CORP COM STK (DE) position peaked at $901K in Q2 2016.
  • 111 funds tracked by Wall St. Rank held RAPTOR PHARMACEUTICAL CORP COM STK (DE) as of Q3 2016.

Based on Jacobs Levy Equity Management's 13F filing for Q3 2016, filed 14 Nov 2016.